GEHC
GE HealthCare Technologies Inc. NASDAQ$61.03
Mkt Cap $28.1B
52w Low $58.75
7.4% of range
52w High $89.77
50d MA $73.97
200d MA $76.59
P/E (TTM)
13.4x
EV/EBITDA
11.3x
P/B
2.6x
Debt/Equity
1.0x
ROE
17.9%
P/FCF
24.9x
RSI (14)
—
ATR (14)
—
Beta
1.31
50d MA
$73.97
200d MA
$76.59
Avg Volume
3.9M
About
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 1.07 | 0.99 | -7.5% | 59.49 | -0.5% | +2.3% | +2.6% | — | — | — | — | — |
| Feb 4, 2026 | TNS | 1.40 | 1.44 | +2.9% | 82.63 | -0.4% | -0.4% | -2.4% | -4.3% | -4.1% | -4.2% | -10.1% | — |
| Oct 29, 2025 | TNS | 1.05 | 1.07 | +1.9% | 77.38 | +0.0% | -3.1% | -3.1% | -3.8% | -4.0% | -2.3% | +3.4% | — |
| Jul 30, 2025 | TNS | 0.92 | 1.06 | +15.5% | 71.64 | +1.0% | -0.4% | -2.5% | -1.4% | -1.3% | -2.3% | +2.9% | — |
| Apr 30, 2025 | TNS | 0.91 | 1.01 | +10.5% | 70.33 | -0.0% | -3.8% | +0.3% | -1.4% | -4.6% | -2.1% | +0.3% | — |
| Feb 13, 2025 | TNS | 1.26 | 1.45 | +15.1% | 93.48 | -0.3% | -1.4% | -0.9% | -1.0% | -1.5% | -2.6% | -11.8% | — |
| Oct 30, 2024 | TNS | 1.05 | 1.14 | +8.6% | 87.20 | -1.2% | +0.2% | -0.3% | -0.2% | +1.1% | -0.5% | -4.6% | — |
| Jul 31, 2024 | TNS | 0.98 | 1.00 | +2.0% | 84.63 | -0.6% | -1.5% | -1.4% | -3.7% | -3.6% | -6.3% | +0.2% | — |
| Apr 30, 2024 | TNS | 0.91 | 0.90 | -1.1% | 76.24 | +0.4% | +2.6% | +2.1% | +4.2% | +4.7% | +6.8% | +3.1% | — |
| Feb 6, 2024 | TNS | 1.07 | 1.18 | +10.3% | 81.96 | +0.1% | -0.2% | +0.1% | -0.8% | +1.5% | +0.4% | +13.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 30 | Citigroup | Maintains | Neutral → Neutral | — | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 30 | JP Morgan | Maintains | Neutral → Neutral | — | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 30 | Goldman Sachs | Downgrade | Buy → Neutral | $65 | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $59.49 | $59.21 | -0.5% | +2.3% | +2.6% | — | — | — |
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $68.50 | $62.15 | -9.3% | -13.2% | -11.2% | -10.9% | — | — |
| Apr 21 | BTIG | Maintains | Buy → Buy | — | $74.15 | $74.43 | +0.4% | -2.5% | -3.7% | -5.7% | -7.2% | -4.9% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $73.20 | $75.04 | +2.5% | +2.0% | +1.3% | -1.3% | -2.5% | -4.5% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $73.18 | $72.62 | -0.8% | +0.9% | +2.0% | +0.5% | +0.0% | +2.0% |
Recent Filings
8-K
GE HealthCare Technologies Inc. -- 8-K Filing
GE HealthCare exceeded topline expectations at year-start, with strong growth in Pharmaceutical Diagnostics, Advanced Visualization, and Imaging segments driving performance.
Apr 29
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis from this filing summary, as it contains only technical XBRL metadata and XML schema references without actual business substance or financial information relevant to GEHC or PH stock performance.
Mar 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kevin A.'s appointment as CEO following Mihaljevic's departure creates leadership uncertainty at GE Healthcare, potentially pressuring the stock until investors assess the new leader's strategic vision and execution capability.
Mar 17
8-K · 1.01
! Medium
GE HealthCare Technologies Inc. -- 8-K 1.01: Financing / Debt Agreement
GE HealthCare replaced its $500 million 364-day revolving credit facility with a new agreement maturing February 2027, providing continued liquidity access through JPMorgan Chase Bank.
Feb 27
8-K
GE HealthCare Technologies Inc. -- 8-K Filing
GE HealthCare exceeded Q4 2025 revenue and EPS expectations with 7.1% total revenue growth and 4.8% organic growth, demonstrating operational momentum as a standalone public company.
Feb 4
Data updated apr 25, 2026 11:06am
· Source: massive.com